A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Progressive Supranuclear Palsy

In brief

The purpose of this study was to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in participants with progressive supranuclear palsy (PSP).

Key facts

Study ID
NCT02985879
Run by
AbbVie
People needed
378
Starts
2016-12-12
Expected to finish
2019-11-20
Last updated by the study team
2021-02-03

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.